GME751
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GME751, covering 2026-04-09 to 2026-04-23. Get the full timeline:
Most recent: Clinical Trial Update: A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma [Phase 1]